We Pioneered a Technology to Save Millions of Poor Children, But a Worldwide Smear Campaign Has Blocked It

We Pioneered a Technology to Save Millions of Poor Children, But a Worldwide Smear Campaign Has Blocked It

On left, a picture of white rice next to Golden Rice, and on right, a girl who lost one eye due to vitamin A deficiency.

(Photo Credit: Golden Rice Humanitarian Board)


Keep ReadingKeep Reading
Adrian Dubock, Ingo Potrykus, Peter Beyer
Peter Beyer headed a research group at University of Freiburg, Germany, with a strong focus on improving the nutritional value of crop plants. Ingo Potrykus worked at ETH Zurich, Switzerland, with a research group using genetic engineering technology applied to "food security" crops in developing countries. Adrian Dubock designed the international collaboration, and its governance, for turning the results of the Potrykus and Beyer teams into a useful product – Golden Rice - to combat vitamin A deficiency, a long-standing objective which all three share. Potrykus is the Chair of the Golden Rice Humanitarian Board, Beyer and Dubock are Board members, and Dubock is also the Executive Secretary of the Board. In common with other Board members, all three are unpaid volunteers.
How sharing, hearing, and remembering positive stories can help shape our brains for the better

Across cultures and through millennia, human beings have always told stories. Whether it’s a group of boy scouts around a campfire sharing ghost stories or the paleolithic Cro-Magnons etching pictures of bison on cave walls, researchers believe that storytelling has been universal to human beings since the development of language.

But storytelling was more than just a way for our ancestors to pass the time. Researchers believe that storytelling served an important evolutionary purpose, helping humans learn empathy, share important information (such as where predators were or what berries were safe to eat), as well as strengthen social bonds. Quite literally, storytelling has made it possible for the human race to survive.

Keep ReadingKeep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.

A new type of cancer therapy is shrinking deadly brain tumors with just one treatment

MRI scans after a new kind of immunotherapy for brain cancer show remarkable progress in one patient just days after the first treatment.

Mass General Hospital

Few cancers are deadlier than glioblastomas—aggressive and lethal tumors that originate in the brain or spinal cord. Five years after diagnosis, less than five percent of glioblastoma patients are still alive—and more often, glioblastoma patients live just 14 months on average after receiving a diagnosis.

But an ongoing clinical trial at Mass General Cancer Center is giving new hope to glioblastoma patients and their families. The trial, called INCIPIENT, is meant to evaluate the effects of a special type of immune cell, called CAR-T cells, on patients with recurrent glioblastoma.

Keep ReadingKeep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.